Arcturus Therapeutics Holdings Inc. (ARCT)

Market Cap	210.61M -36.4%
Revenue (ttm)	29.37M -76.0%
Net Income	-93.28M
EPS	-3.33
Shares Out	28.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,461,642
Open	6.47
Previous Close	6.08
Day's Range	6.45 - 7.56
52-Week Range	5.50 - 24.17
Beta	2.27
Analysts	Buy
Price Target	20.20 (+172.61%)
Earnings Date	Aug 6, 2026

About ARCT

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 111
• Stock Exchange: NASDAQ
• Ticker Symbol: ARCT
• Website: https://arcturusrx.com

Financial Performance

In 2025, ARCT's revenue was $82.03 million, a decrease of -46.14% compared to the previous year's $152.31 million. Losses were -$65.78 million, -18.73% less than in 2024.

Analyst Summary

According to 13 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price target is $20.2, which is an increase of 172.61% from the latest price.

Price Target

$20.2

(172.61% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 10, 2026

Data Sources Report a data error